Strength in quality: Myosteatosis as a predictor of survival in advanced hepatocellular carcinoma.
作者信息
Campani Claudia, Berzigotti Annalisa
机构信息
Internal Medicine and Liver Unit, University Hospital Careggi, University of Florence, Florence, Italy.
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
出版信息
United European Gastroenterol J. 2024 Oct;12(8):1002-1003. doi: 10.1002/ueg2.12645. Epub 2024 Aug 2.
Abstract
摘要
相似文献
1
Strength in quality: Myosteatosis as a predictor of survival in advanced hepatocellular carcinoma.质量中的力量：肌少脂性作为晚期肝细胞癌生存的预测指标
United European Gastroenterol J. 2024 Oct;12(8):1002-1003. doi: 10.1002/ueg2.12645. Epub 2024 Aug 2.
2
Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.骨骼肌减少症和肌内脂肪变性与接受免疫治疗的晚期肝细胞癌患者的生存相关。
Eur Radiol. 2023 Jan;33(1):512-522. doi: 10.1007/s00330-022-08980-4. Epub 2022 Jul 21.
3
Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.进行性肌肉减少症和肌内脂肪增多症可预测接受免疫检查点抑制剂治疗的晚期 HCC 患者的预后。
Front Immunol. 2024 Apr 16;15:1396927. doi: 10.3389/fimmu.2024.1396927. eCollection 2024.
4
Clinical impact of myosteatosis measured by magnetic resonance imaging on long-term outcomes of hepatocellular carcinoma after radical hepatectomy.磁共振成像测量的肌内脂肪含量对肝癌根治性切除术后长期结局的临床影响。
BMC Surg. 2023 Sep 15;23(1):281. doi: 10.1186/s12893-023-02188-z.
5
Association of myosteatosis with treatment response and survival in patients with hepatocellular carcinoma undergoing chemoembolization: a retrospective cohort study.肌内脂肪浸润与接受化疗栓塞治疗的肝细胞癌患者治疗反应和生存的关系：一项回顾性队列研究。
Sci Rep. 2023 Mar 9;13(1):3978. doi: 10.1038/s41598-023-31184-9.
6
Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial.索拉非尼治疗晚期肝细胞肝癌患者的 SIRT 与索拉菲尼治疗：SORAMIC 试验的亚分析结果提示骨骼肌质量与总生存相关。
United European Gastroenterol J. 2024 Oct;12(8):1016-1027. doi: 10.1002/ueg2.12627. Epub 2024 Jul 15.
7
Chitinase-3 like-protein-1, a prognostic biomarker in patients with hepatocellular carcinoma and concomitant myosteatosis.壳三糖酶蛋白 1 是合并肌内脂肪变性的肝细胞癌患者的预后生物标志物。
BMC Cancer. 2024 Aug 23;24(1):1042. doi: 10.1186/s12885-024-12808-3.
8
Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease is associated with heterogeneous pattern of fat infiltration in skeletal muscles.非酒精性脂肪性肝病患者的肝细胞癌与骨骼肌内脂肪浸润的异质性模式相关。
Eur Radiol. 2024 Mar;34(3):1461-1470. doi: 10.1007/s00330-023-10131-2. Epub 2023 Sep 2.
9
Myosteatosis can Predict Unfavorable Outcomes in Advanced Hepatocellular Carcinoma Patients Treated With Hepatic Artery Infusion Chemotherapy and Anti-PD-1 Immunotherapy.肌少脂症可预测接受肝动脉灌注化疗和抗PD-1免疫治疗的晚期肝细胞癌患者的不良预后。
Front Oncol. 2022 May 16;12:892192. doi: 10.3389/fonc.2022.892192. eCollection 2022.
10
Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma.肌脂肪变性和肌肉流失影响男性肝细胞癌患者的肝移植结局。
J Cachexia Sarcopenia Muscle. 2024 Oct;15(5):2071-2083. doi: 10.1002/jcsm.13554. Epub 2024 Aug 27.
本文引用的文献
1
Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial.索拉非尼治疗晚期肝细胞肝癌患者的 SIRT 与索拉菲尼治疗：SORAMIC 试验的亚分析结果提示骨骼肌质量与总生存相关。
United European Gastroenterol J. 2024 Oct;12(8):1016-1027. doi: 10.1002/ueg2.12627. Epub 2024 Jul 15.
2
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.肌少脂症与肌肉减少症密切相关，并且在肝硬化患者中会导致明显更差的预后。
J Hepatol. 2024 Oct;81(4):641-650. doi: 10.1016/j.jhep.2024.05.020. Epub 2024 May 21.
3
Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.进行性肌肉减少症和肌内脂肪增多症可预测接受免疫检查点抑制剂治疗的晚期 HCC 患者的预后。
Front Immunol. 2024 Apr 16;15:1396927. doi: 10.3389/fimmu.2024.1396927. eCollection 2024.
4
Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy.白蛋白-肌内脂变性指数作为一线化疗的晚期胰腺癌患者的预后因素。
Int J Clin Oncol. 2024 Jun;29(6):822-831. doi: 10.1007/s10147-024-02512-4. Epub 2024 Apr 2.
5
The Clinical Significance of Myosteatosis in Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib.索拉非尼治疗的肝细胞癌患者中肌少脂变对生存结局的临床意义
Cancers (Basel). 2024 Jan 20;16(2):454. doi: 10.3390/cancers16020454.
6
The predictive value of sarcopenia and myosteatosis in trans-arterial (chemo)-embolization treated HCC patients.肌肉减少症和肌肉脂肪变性对经动脉（化疗）栓塞治疗 HCC 患者的预测价值。
Aging (Albany NY). 2024 Jan 5;16(1):389-401. doi: 10.18632/aging.205375.
7
Clinical impact of myosteatosis measured by magnetic resonance imaging on long-term outcomes of hepatocellular carcinoma after radical hepatectomy.磁共振成像测量的肌内脂肪含量对肝癌根治性切除术后长期结局的临床影响。
BMC Surg. 2023 Sep 15;23(1):281. doi: 10.1186/s12893-023-02188-z.
8
Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial.晚期肝细胞癌患者体成分的影响：SORAMIC 试验的亚分析。
Hepatol Commun. 2023 May 23;7(6). doi: 10.1097/HC9.0000000000000165. eCollection 2023 Jun 1.
9
Association of myosteatosis with treatment response and survival in patients with hepatocellular carcinoma undergoing chemoembolization: a retrospective cohort study.肌内脂肪浸润与接受化疗栓塞治疗的肝细胞癌患者治疗反应和生存的关系：一项回顾性队列研究。
Sci Rep. 2023 Mar 9;13(1):3978. doi: 10.1038/s41598-023-31184-9.
10
Albumin-myosteatosis gauge as a novel prognostic risk factor in patients with non-metastatic colorectal cancer.白蛋白-肌内脂变指标作为一种新型的非转移性结直肠癌患者的预后危险因素。
J Cachexia Sarcopenia Muscle. 2023 Apr;14(2):860-868. doi: 10.1002/jcsm.13183. Epub 2023 Jan 25.
Zotero 插件